Published in Clin Cancer Res on February 09, 2010
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma (CAP) | NCT00132301
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2014) 3.10
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate (2013) 1.15
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem (2012) 0.99
Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed (2011) 0.99
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res (2012) 0.88
Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer. Yonsei Med J (2015) 0.84
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate (2012) 0.84
Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion. J Biol Chem (2015) 0.81
Abiraterone acetate. Nat Rev Drug Discov (2011) 0.80
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A (2004) 3.68
The endocrinology and developmental biology of the prostate. Endocr Rev (1987) 3.58
Reactive stroma in prostate cancer progression. J Urol (2001) 3.21
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
Therapeutic targeting of the tumor microenvironment. Cancer Cell (2005) 2.86
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (2001) 2.85
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res (2001) 2.50
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (1993) 2.31
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Can cancer be reversed by engineering the tumor microenvironment? Semin Cancer Biol (2008) 2.07
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem (2007) 1.87
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
Epithelial-mesenchymal interactions in prostatic development. I. morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol (1983) 1.38
Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer (2006) 1.33
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology (2004) 1.25
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets (2009) 1.25
Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res (2005) 1.25
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer. Cancer Res (2008) 1.11
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer (2008) 1.10
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology (2003) 1.10
Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol (2000) 1.05
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol (2005) 1.03
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology (2007) 0.97
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol (2007) 0.96
Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int (2000) 0.94
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer (2006) 0.92
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int (2006) 0.92
Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J Cell Biochem (2009) 0.91
Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev (1991) 0.90
FGF signaling in prostate tumorigenesis--new insights into epithelial-stromal interactions. Cancer Cell (2007) 0.89
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clin Genitourin Cancer (2007) 0.88
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol (2009) 0.85
Morphologic and biochemical alterations in rat prostatic tumors induced by fetal urogenital sinus mesenchyme. Prostate (1990) 0.83
The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res (2003) 0.82
Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol (1996) 0.80
The role of 'notch' in urological cancers. BJU Int (2009) 0.77
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 1.46
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
Bortezomib as a potential treatment for prostate cancer. Cancer Res (2004) 1.29
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics (2009) 1.11
Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem (2004) 1.10
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A (2011) 1.09
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis (2002) 1.08
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res (2007) 1.07
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol (2002) 1.06
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.05
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res (2002) 1.04
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol (2005) 1.03
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Inform (2007) 0.99
Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep (2003) 0.99
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res (2005) 0.98
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res (2004) 0.95
Prioritizing genes associated with prostate cancer development. BMC Cancer (2010) 0.94
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int (2009) 0.94
Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov (2011) 0.93
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res (2004) 0.93
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 0.92
Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia (2005) 0.91
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev (2004) 0.91
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther (2009) 0.91
Housekeeping genes in prostate tumorigenesis. Int J Cancer (2009) 0.90
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys (2012) 0.89
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2006) 0.88
Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol (2009) 0.88
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One (2012) 0.88
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther (2009) 0.88
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol (2003) 0.87
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate (2007) 0.87
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res (2008) 0.87
Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One (2011) 0.86
Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw (2006) 0.85
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol (2004) 0.84
Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate (2004) 0.84
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate (2012) 0.84
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer (2003) 0.83
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene (2004) 0.83
Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res (2004) 0.83
Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol (2010) 0.82
Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate (2011) 0.81
Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development. J Bioinform Comput Biol (2012) 0.81
Abiraterone acetate. Nat Rev Drug Discov (2011) 0.80
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol (2002) 0.79
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate (2013) 0.78
Informative clinical investigation: a demanding taskmaster. J Clin Oncol (2009) 0.78
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer (2003) 0.78
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J Oncol Pract (2013) 0.78
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer (2014) 0.77
Building a statistical model for predicting cancer genes. PLoS One (2012) 0.77
Prostate cancer: thalidomide for prostate cancer: is there progress? Nat Rev Urol (2009) 0.75
Challenge of locally persistent prostate cancer: an unresolved clinical dilemma. J Clin Oncol (2002) 0.75
In silico functional profiling of individual prostate cancer tumors: many genes, few functions. Cancer Genomics Proteomics (2012) 0.75
Variant prostate carcinoma and elevated serum CA-125. Can J Urol (2014) 0.75